Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2026-03-04 @ 10:50 PM
Study NCT ID:
NCT04702360
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-07-15
First Post:
2021-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
VX20-445-905
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None